Official announcements from European regulatory bodies or Immunocore

NHS Offers KIMMTRAK to HLA-A*02:01-Positive Adults with Previously Untreatable Uveal Melanoma

Dec 3, 2024, 07:10 AM

A significant advancement in cancer treatment has been announced in England, with hundreds of patients diagnosed with unresectable or metastatic uveal melanoma set to receive access to KIMMTRAK, a pioneering drug developed by Immunocore. The National Health Service (NHS) confirmed that this reimbursement agreement will allow HLA-A*02:01-positive adults to access the treatment, which is expected to extend their lives by several months. This breakthrough, described as a 'game changer,' was developed by a research team in Oxford and marks a major milestone for patients suffering from this rare and previously untreatable form of eye cancer.